Pyrazolo pyridine derivatives as nadph oxidase inhibitors

A method for the treatment or prophylaxis of a patient suffering from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, disorders of the gastrointestinal system, angiogenesis, angiogenesis-dependent conditions and other diseases and disorders associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase), the method comprising administering a pyrazolo pyridine derivative according to Formula (I):

• wherein G1 is selected from H;
• optionally substituted acyl;
• optionally substituted acyl C1-C6 alkyl;
• optionally substituted alkyl C3-C8-cycloalkyl alkyl;
• optionally substituted heterocycloalkyl alkyl;
• optionally substituted aryl alkyl;
• and optionally substituted heteroaryl alkyl;
• G2 is selected from —CHR1R2 and a saturated ring system selected from optionally substituted C3-C8-cycloalkyl and optionally substituted heterocycloalkyl;
• R1 and R2 are independently selected from H;
• optionally substituted alkoxy;
• optionally substituted alkoxy C1-C6 alkyl;
• optionally substituted amino;
• optionally substituted aminoalkyl;
• optionally substituted acyl;
• C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl;
• optionally substituted C2-C6 alkynyl;
• optionally substituted aryl;
• optionally substituted C1-C6 alkyl aryl;
• optionally substituted aryl C1-C6 alkyl;
• optionally substituted heteroaryl;
• optionally substituted C1-C6 alkyl heteroaryl;
• optionally substituted heteroaryl C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl aryl;
• optionally substituted aryl C2-C6 alkenyl;
• optionally substituted C2-C6 alkenyl heteroaryl;
• optionally substituted heteroaryl C2-C6 alkenyl;
• optionally substituted C3-C8-cycloalkyl;
• optionally substituted heterocycloalkyl;
• optionally substituted C1-C6 alkyl C3-C8-cycloalkyl;
• optionally substituted C3-C8-cycloalkyl C1-C6 alkyl;
• optionally substituted C1-C6 alkyl heterocycloalkyl and optionally substituted heterocycloalkyl C1-C6 alkyl;
• or —CHR1R2 form together a ring selected from optionally substituted C3-C8-cycloalkyl and optionally substituted heterocycloalkyl;
• G3 is selected from H;
• optionally substituted amino;
• optionally substituted aminoalkyl;
• optionally substituted aminocarbonyl;
• optionally substituted alkoxy;
• optionally substituted alkoxy C1-C6 alkyl;
• optionally substituted carbonyl;
• optionally substituted C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl;
• optionally substituted C2-C6 alkynyl;
• optionally substituted aryl;
• optionally substituted aryl C1-C6 alkyl;
• optionally substituted heteroaryl;
• optionally substituted C1-C6 alkyl heteroaryl;
• optionally substituted heteroaryl C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl aryl;
• optionally substituted aryl C2-C6 alkenyl;
• optionally substituted C2-C6 alkenyl heteroaryl;
• optionally substituted heteroaryl C2-C6 alkenyl;
• optionally substituted C3-C8-cycloalkyl;
• optionally substituted heterocycloalkyl;
• optionally substituted C1-C6 alkyl C3-C8-cycloalkyl;
• optionally substituted C3-C8-cycloalkyl C1-C6 alkyl;
• optionally substituted C1-C6 alkyl heterocycloalkyl and optionally substituted heterocycloalkyl C1-C6 alkyl;
• G4 is selected from H;
• optionally substituted acyl;
• optionally substituted acyl amino;
• optionally substituted acyl C1-C6 alkyl;
• optionally substituted C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl;
• optionally substituted C2-C6 alkynyl;
• optionally substituted aryl;
• optionally substituted C1-C6 alkyl aryl;
• optionally substituted aryl C1-C6 alkyl;
• optionally substituted heteroaryl;
• optionally substituted C1-C6 alkyl heteroaryl;
• optionally substituted heteroaryl C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl aryl;
• optionally substituted aryl C2-C6 alkenyl;
• optionally substituted C2-C6 alkenyl heteroaryl;
• optionally substituted heteroaryl C2-C6 alkenyl;
• optionally substituted C3-C8-cycloalkyl;
• optionally substituted heterocycloalkyl;
• optionally substituted C1-C6 alkyl C3-C8-cycloalkyl;
• optionally substituted C3-C8-cycloalkyl C1-C6 alkyl;
• optionally substituted C1-C6 alkyl heterocycloalkyl and optionally substituted heterocycloalkyl C1-C6 alkyl;
• G5 is selected from H;
• optionally substituted C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl;
• optionally substituted C2-C6 alkynyl;
• optionally substituted aryl;
• optionally substituted C1-C6 alkyl aryl;
• optionally substituted aryl C1-C6 alkyl;
• optionally substituted heteroaryl;
• optionally substituted C1-C6 alkyl heteroaryl;
• optionally substituted heteroaryl C1-C6 alkyl;
• optionally substituted C2-C6 alkenyl aryl;
• optionally substituted aryl C2-C6 alkenyl;
• optionally substituted C2-C6 alkenyl heteroaryl;
• optionally substituted heteroaryl C2-C6 alkenyl;
• optionally substituted C3-C8-cycloalkyl;
• optionally substituted heterocycloalkyl;
• optionally substituted C1-C6 alkyl C3-C8-cycloalkyl;
• optionally substituted C3-C8-cycloalkyl C1-C6 alkyl;
• optionally substituted C1-C6 alkyl heterocycloalkyl and optionally substituted heterocycloalkyl C1-C6 alkyl;
• or a tautomer, geometrical isomer, optically active form as enantiomer, diastereomer and racemate forms or a pharmaceutically acceptable salt thereof, to a patient in need of treatment of said disease or condition.